There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Capricor Therapeutics (CAPR), AzurRx BioPharma Inc (AZRX) and Biospecifics Technologies Corp (BSTC) with bullish sentiments.
Capricor Therapeutics (CAPR)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics today and set a price target of $19.50. The company’s shares closed last Monday at $2.48, close to its 52-week low of $2.30.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.5% and a 25.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.
See today’s analyst top recommended stocks >>
AzurRx BioPharma Inc (AZRX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma Inc today and set a price target of $5.00. The company’s shares closed last Monday at $0.47, close to its 52-week low of $0.46.
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -20.2% and a 31.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd ADR, EyePoint Pharmaceuticals Inc, and Stealth Biotherapeutics Corp.
AzurRx BioPharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
Biospecifics Technologies Corp (BSTC)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Biospecifics Technologies Corp today and set a price target of $90.00. The company’s shares closed last Monday at $50.94, close to its 52-week low of $49.11.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -22.2% and a 18.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Turning Point Therapeutics Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Biospecifics Technologies Corp is a Moderate Buy with an average price target of $90.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
